A stiff, painful elbow that locks at the ends of its arc — often dismissed as "just arthritis" — can respond remarkably well to treatment when the right procedure is matched to the stage of disease. Dr. R. David Graham at Jacksonville Orthopaedic Institute offers targeted injection management, open debridement for early and moderate disease, and total elbow arthroplasty for advanced cases — with revision arthroplasty accepted.
The dominant complaint guides the procedure. Stiffness and motion loss with tolerable pain — debridement. Severe pain with destroyed joint surfaces — arthroplasty. Many patients are surprised that a stiff arthritic elbow can regain functional motion without joint replacement.
The Core Question
Two factors drive the surgical decision: how much viable joint surface remains, and whether stiffness or pain is the dominant complaint. Early disease with motion loss is a debridement problem. Advanced disease with pain and joint destruction is an arthroplasty problem.
Meaningful joint surface remains. Patient cannot fully straighten or fully bend the elbow. Osteophytes at the olecranon tip and coronoid are impinging. Pain is present but manageable — stiffness is the primary functional limitation.
Removal of osteophytes, loose bodies, and impinging tissue — restoring a functional arc of motion without replacing the joint. The Outerbridge-Kashiwagi technique accesses both the anterior and posterior compartments through a single posterior approach, allowing comprehensive debridement in one operation.
Severe joint surface destruction — primary OA at end stage, post-traumatic arthritis with bone-on-bone changes, or RA with pan-articular destruction. Pain is the dominant complaint and limits function even at rest. Debridement cannot address what is essentially absent cartilage.
Replacement of the arthritic humeroulnar joint with a prosthetic implant. Dr. Graham performs both linked and unlinked total elbow arthroplasty and accepts revision cases. The permanent 5 lb repetitive / 10 lb single-effort activity restriction is discussed thoroughly before proceeding. Full detail on the dedicated arthroplasty page.
Regardless of disease stage, injections are used before surgery to manage symptoms, confirm the joint responsible for pain, and determine whether adequate non-operative relief is achievable.
Cortisone injection into the elbow joint for rapid pain relief. PRP as a biologically targeted alternative or complement — particularly for early-to-moderate disease where cartilage biology is still modifiable. Both are offered; the choice depends on disease stage and patient preference.
Causes of Elbow Arthritis
Elbow arthritis develops through several distinct routes — each producing joint damage through different mechanisms, but ultimately leading to the same functional limitations of pain, stiffness, and loss of motion.
Primary elbow OA is more common than often recognized — particularly in dominant-arm dominant males who have spent decades in heavy manual labor or throwing sports. Repetitive high-load joint compression gradually degrades the articular cartilage, producing osteophytes at the olecranon tip, coronoid, and radial head that progressively block the terminal arc of flexion and extension. The classic presentation is a patient who can reach 90° of flexion comfortably but loses the last 20–30° in both directions.
Prior elbow fractures — particularly distal humerus fractures, radial head fractures, and olecranon fractures — can damage the articular cartilage directly at the time of injury or create joint incongruity that accelerates wear over subsequent years. Prior dislocations, ligament injuries, and childhood elbow fractures (especially lateral condyle fractures) also contribute. Post-traumatic arthritis may present at a younger age than primary OA and can produce complex intra-articular scarring alongside the cartilage loss.
RA affects the elbow in up to 50% of patients with longstanding disease. The synovial proliferation characteristic of RA erodes the articular cartilage from the inside — typically producing a more diffuse pattern of joint destruction than primary OA, often involving the radiocapitellar joint and the proximal radioulnar joint in addition to the humeroulnar articulation. RA elbows are often more globally destroyed and may have poor bone quality, making arthroplasty technically more demanding. Rheumatologist optimization before surgery is required.
Gout can affect the elbow — tophi deposits in the olecranon bursa are common, and intramarticular urate crystal deposition produces episodic inflammatory arthritis that over time damages the joint surfaces. Patients with gout often present with a combination of acute flares and chronic background pain. Management of the underlying hyperuricemia is a prerequisite for any surgical discussion; Dr. Graham coordinates with the patient's rheumatologist or primary care physician on uric acid management.
Calcium pyrophosphate deposition disease (CPPD, formerly called pseudogout) produces crystal-induced inflammatory arthritis similar in its acute presentation to gout, but caused by calcium pyrophosphate crystals rather than urate. CPPD can affect the elbow and produce both episodic flares and chronic articular damage. Injection management and systemic treatment of the underlying metabolic condition are coordinated alongside any surgical planning.
Elbow OA almost universally produces loose bodies — osteochondral fragments that break off from arthritic joint surfaces or osteophytes and float freely in the joint. Loose bodies cause intermittent locking, catching, and sharp pain superimposed on the baseline arthritic pain. Their removal — accomplished at the time of open debridement — often provides significant symptomatic relief even in the context of ongoing arthritis, and is one of the more satisfying aspects of elbow debridement surgery.
Recognizing Elbow Arthritis
Elbow arthritis has a recognizable presentation — progressive motion loss at the terminal arc, pain at end range, and intermittent locking from loose bodies. Knowing the pattern helps distinguish it from lateral epicondylitis, cubital tunnel, and other common elbow conditions.
The hallmark of primary elbow OA is loss of the last 20–30° of both extension and flexion. Patients can typically reach functional range (30–130°) but cannot fully straighten or fully bend the elbow. This "arc restriction" — painful end-range block — is what distinguishes OA from soft tissue conditions that produce pain without bony block to motion.
Intermittent locking — the elbow suddenly jamming at a point in the arc and refusing to move — is the classic loose body symptom. Some patients describe it as "catching" rather than complete locking. The episode resolves spontaneously as the loose body shifts position. Locking episodes are often the presenting complaint that brings the patient to evaluation even before constant pain develops.
Pain at the extremes of elbow motion — reaching fully overhead or fully straightening the arm — provoked by the osteophytes impinging as they compress against each other. In primary OA, pain through the mid-arc is initially tolerable; it is the terminal arc where the osteophytes make contact that hurts most. Advanced disease produces pain throughout the arc and eventually at rest.
Loss of elbow flexion impairs the ability to bring objects to the mouth and face. Loss of extension impairs overhead reach and pushing tasks. Reduced elbow flexion arc significantly limits activities of daily living — eating, grooming, dressing — as well as work tasks requiring reaching and carrying. Patients with advanced disease may be unable to perform basic self-care comfortably.
Active inflammatory flares — whether from OA, RA, gout, or CPPD — produce joint effusion and warmth. The elbow has less subcutaneous tissue overlying the joint than most large joints, so effusion is often visible as fullness in the posterior triangular space between the olecranon and epicondyles. Recurrent effusions from inflammatory arthritis accelerate cartilage destruction.
Elbow arthritis — particularly severe flexion contractures — can compress the ulnar nerve at the cubital tunnel, producing numbness, tingling, or weakness in the ring and small fingers. Dr. Graham assesses the ulnar nerve at every elbow arthritis evaluation. When nerve compression is confirmed alongside arthritis, both may be addressed at the same surgical setting.
Non-Surgical Management
Both cortisone and PRP are offered for elbow arthritis. The choice depends on disease stage, patient preference, and how well each modality has worked in the past.
A targeted cortisone injection into the elbow joint reduces the inflammatory component of arthritis pain — particularly useful during active flares in OA, RA, gout, and CPPD. The injection is placed into the radiocapitellar joint or the posterior compartment depending on where the dominant pathology lies. Relief typically lasts weeks to months depending on disease severity and the inflammatory component present.
Cortisone is used before surgery in all elbow arthritis patients — both to provide interim symptom relief and to confirm that the elbow joint is the primary pain source. A patient who receives significant benefit from intra-articular cortisone has confirmed the diagnosis; a patient who receives no benefit warrants further workup before committing to surgery.
Platelet-Rich Plasma is offered alongside cortisone as a biologically targeted injection for elbow arthritis. PRP delivers concentrated growth factors directly into the joint, targeting the degenerative and inflammatory processes rather than simply suppressing them. It is most relevant for early-to-moderate arthritis where meaningful cartilage surface remains and biological stimulation may slow the arthritic progression.
For patients with early OA who want to manage the condition without cortisone, or for patients considering debridement who want to extend the non-operative window first, PRP is a meaningful option. It has no steroid-related side effects and is appropriate for patients where repeated cortisone is less desirable. PRP is cash-pay and not covered by insurance.
Regenerative Option
The elbow joint — particularly in primary OA and early post-traumatic arthritis — often retains meaningful cartilage in the mid-arc even as the terminal range is blocked by osteophytes. In this stage, PRP's biological action on the remaining cartilage and synovial environment is most relevant. Delivering concentrated growth factors into a joint that still has viable tissue to respond is a different proposition from injecting an end-stage bone-on-bone elbow where no cartilage remains to be augmented.
For patients in the early-to-moderate OA category who are managing with periodic injections — or who want to delay debridement — PRP fits naturally into the management sequence. It can be used alongside cortisone, alternating with it, or as the primary injection approach for patients who prefer to avoid steroid exposure. Dr. Graham is happy to discuss candidacy at your appointment.
For patients with advanced RA or end-stage primary OA heading toward arthroplasty, PRP has less to offer — the biology of the joint is beyond the point where growth factor stimulation is meaningful, and surgery is the appropriate next step. The conversation about PRP candidacy includes an honest assessment of where in this spectrum each individual patient sits.
Surgical Treatment
Open debridement for the patient whose elbow still has viable joint surface but has lost motion. Total elbow arthroplasty for the patient whose joint is destroyed and pain is the limiting factor.
Open elbow debridement — using the Outerbridge-Kashiwagi technique or a similar posterior approach — is one of the most underappreciated procedures in elbow surgery. Patients who have been told their arthritic elbow simply needs a replacement are sometimes surprised to learn that a debridement can restore a functional arc of motion, remove the loose bodies causing locking, and provide meaningful pain relief while preserving the native joint. For the right patient at the right stage of disease, it is highly effective.
Performed at Baptist Beaches Hospital or Horizon Surgery Center as a same-day outpatient procedure. Regional block (brachial plexus) with or without sedation or general anesthesia. Tourniquet on the upper arm. The patient is positioned prone or lateral to allow posterior elbow access.
A posterior midline elbow incision provides access to the olecranon fossa. The ulnar nerve is identified and assessed — if there is evidence of cubital tunnel compression, it may be decompressed or transposed at this setting. The posterior compartment is opened and the olecranon tip osteophyte and posterior loose bodies are addressed first.
A key technical step of the OK procedure: a window is created through the floor of the olecranon fossa into the anterior compartment of the elbow. This fenestration allows the surgeon to access the anterior compartment — where the coronoid osteophyte and anterior loose bodies reside — through the same posterior incision without the need for a separate anterior approach. It is the technical innovation that makes comprehensive debridement possible through a single incision.
All impinging osteophytes are removed — at the olecranon tip, the coronoid, the radial head rim, and the humeral condyles as needed. All loose bodies in both the posterior and anterior compartments are extracted. Contracted capsular tissue limiting motion may be released. The goal is to restore a smooth arc of flexion and extension by eliminating all bony and soft-tissue impingement.
The full arc of elbow motion is assessed under anesthesia after debridement to confirm the expected motion restoration. The wound is closed in layers. A posterior splint is applied in extension for the first few days for comfort, then removed to begin early range-of-motion exercises. Formal therapy begins within the first week.
When elbow arthritis has destroyed the joint surfaces beyond what debridement can address — particularly in rheumatoid arthritis and end-stage primary OA — total elbow arthroplasty replaces the humeroulnar joint with a prosthetic implant, providing permanent pain relief. Dr. Graham performs both linked and unlinked total elbow arthroplasty and accepts revision cases. The permanent activity restriction (5 lb repetitive / 10 lb single-effort lifting) is discussed thoroughly before any patient proceeds.
Full procedure detail, implant selection, and recovery on the dedicated page.
Linked vs. unlinked implants, surgical technique, the permanent activity restriction, revision arthroplasty — all covered in full on the elbow arthroplasty page.
Before surgery in any patient with rheumatoid or other inflammatory arthritis, Dr. Graham requires coordination with the patient's rheumatologist. Biologic medications — TNF inhibitors and others — are typically held perioperatively to reduce wound healing complications and infection risk. The rheumatologist manages medication timing and restarts.
Bone quality in RA patients is often compromised — this affects implant fixation strategy and the choice between linked and unlinked implants. Systemic disease activity, nutritional status, and skin integrity must all be addressed before proceeding with elbow arthroplasty in an RA patient. Dr. Graham coordinates closely with the treating rheumatologist throughout.
Recovery
Recovery differs significantly between debridement and arthroplasty. Both are outpatient procedures — patients go home the same day.
Posterior splint removed within the first few days. Early active range-of-motion exercises begin immediately — this is the most important phase of recovery. The motion gains achieved in the operating room must be maintained by active exercise before scar tissue reforms.
Structured hand and elbow therapy with progressive motion and strengthening. Dynamic splinting may be used to maintain end-range extension or flexion gains made in surgery. Commitment to therapy during this phase determines the final motion outcome.
In Dr. Graham's experience, most patients return to full work and activity — including manual labor — within 3 to 4 months of open debridement. The restored arc of motion is durable when maintained with regular use.
Posterior splint for wound protection. Gentle active-assisted motion begins within the first week under therapist guidance. Pain is managed with oral medication and ice.
Active range of motion and progressive strengthening through formal therapy. Elbow flexion-extension and forearm rotation restore progressively. The permanent 5 lb / 10 lb activity restriction applies from this point forward.
Most patients reach full functional return — pain-free for all daily activities within the permanent activity restrictions — by 3 to 6 months after total elbow arthroplasty. Full detail on the dedicated arthroplasty page.
"I'd been told I needed a joint replacement. Dr. Graham looked at my imaging, examined my elbow, and told me I was actually a candidate for a less invasive procedure. He was right — I got my motion back and avoided a replacement entirely."
Roy Williams · Elbow Surgery · Verified Google Review ★ 5/5
Common Questions